Compare Amgen, Inc. (AMGN) vs Teradyne, Inc. (TER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Teradyne, Inc. — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Teradyne, Inc. trades at $348.82 (market cap $56.29B). The key difference: Amgen, Inc. is far larger — about 3.5× Teradyne, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | TER | |
|---|---|---|
Market Cap | $196.12B | $56.29B |
Sector | Health | Technology |
52-Week High | $388.16 | $483.84 |
52-Week Low | $271.18 | $90.15 |
Enterprise Value | $241.41B | $56.13B |
Dividend Yield | 2.77% | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Teradyne (TER) trades at $359.60, down 0.87% amid a bearish technical signal, though it remains supported by strong fundamentals including a 22.55% net income margin and consistent earnings beats. Recent news highlights AI-driven data center demand boosting revenue, with Q2 2026 EPS expected at $2.04. The company maintains robust profitability metrics like 28.75% ROE, but faces headwinds from negative net cash flow trends and elevated valuation ratios (P/E 66.72).
Outlook: TER's AI and robotics exposure offers growth potential, with a consensus price target of $453.60 implying 26% upside. Risks include semiconductor cycle volatility and high valuations. Analyst sentiment is bullish (64.5% buy ratings), but investors should monitor execution on Q2 earnings and cash flow improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
